iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/29410723
Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2017 MauiDerm Meeting - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep;10(9 Suppl):S8-S41.
Epub 2017 Sep 1.

Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2017 MauiDerm Meeting

Jo Ann LeQuang  1
Affiliations

Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2017 MauiDerm Meeting

Jo Ann LeQuang. J Clin Aesthet Dermatol. 2017 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

DISCLOSURES:The authors have no conflicts of interest to relevant to the content of this article.

Figures

Figure 1.
Figure 1.
Structure and signaling of IL-17 inhibiting third-generation biologics; IL: interleukin Reproduced with permission from Lønnberg et al. Targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmet Investig Dermatol. 2014;7: 251–259. Published online 2014 Sep 15. doi: 10.2147/CCID.S67534. Copyright © 2014 Lønnberg et al.
Figure 2.
Figure 2.
Tumor necrosis factor-alpha (TNF-α) inhibitor patients also endured a longer time to first major adverse cardiac event (MACE) than methotrexate patients Reproduced with permission from Wu, et al. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate. J Am Acad Dermatol. 2017;76(1):81-90.
Figure 3.
Figure 3.
Actinic keratoses (AK) treatment algorithms Reproduced with permission from Eggert Stockfleth, MD. Copyright © 2012
Figure 4.
Figure 4.
Proportional changes from baseline in the total number of AK lesions during and after treatment for 5-fluorouracil 0.5% combined with salicylic acid 10% (n=108) vs. vehicle patients (n=55). Reproduced with permission from Eggert Stockfleth, MD. Copyright © 2012
Figure 5.
Figure 5.
Lesion clearance by thickness and nodularity; LCC: lesion complete clearance; MAL: methyl aminolevulinate; BF-200: nanoemulsion; ALA: 5-aminolevulinic acid; nBCC: patients with basal cell carcinoma
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Strober B, Bagel J, Lebwohl M, et al. Efficacy and safety of apremilast in patients with moderate plaque psoriasis with lower BSA: week 16 results from the UNVEIL study. J Drugs Dermatol. 2017;16(8):801–808. - PubMed
    1. Gottlieb AB, et al. Certolizumab pegol treatment for chronic plaque psoriasis: 16-week primary results from two phase III, multicenter, randomized, placebo-controlled studies. Abstract 5077. Presented at American Academy of Dermatology 2017 Annual Meeting. 2017 Mar 4.
    1. Final Cimzia (certolizumab pegol) phase 3 trial meets primary efficacy endpoint in patients with moderate to severe chronic plaque psoriasis [news release]. Dermira. http://investor.dermira.com/phoenix.zhtml?c=253686&p=irol-newsArticle&ID... 2017 Jan 18.
    1. Warren RB, Mrowietz U, von Kiedrowski R, et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10068):528–537. - PubMed
    1. Wu JJ, Guerin A, Sundaram M, Dea K, Cloutier M, Mulani P. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate. J Am Acad Dermatol. 2017;76(1):81–90. - PubMed

LinkOut - more resources